This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Lucy Chard
9 Dec 2022

Thermo Fisher Scientific expands with state-of-the-art facility in China

Thermo Fisher Scientific are to open a new cGMP facility in China, including the latest technology so that they can assist in the accelerated provision of medicines to patients. 

Thermo Fisher Scientific has announced that it will be opening a new facility for the development and manufacturing of biologics and steriles in Hangzhou, China. 

The site will mean Thermo fisher are more well placed to address the needs of companies to give quicker access to therapies for patients in China and the Asia-Pacific region. 

"Hangzhou is a strategic addition to our global pharma services network and the latest example of our commitment to meeting customer demands globally,” stated Mike Shafer, Senior Vice President and President, Pharma Services. “We continue to invest in capabilities to support the manufacturing needs of our customers, enabling them to serve more patients throughout the world.”  

The cGMP facility will be 80,000 m2, offering integrated clinical and commercial drug type capabilities, from process development all the way to sterile fill-finish. In the future Thermo Fisher will expand these capabilities to include commercial packaging and labelling. 

The facility will house the latest in technology, including Thermo Fisher 2,000-liter HyPerforma Single-Use Bioreactors and associated Single-Use equipment and this will expand to include bioreactor capacity up to 5,000 litres through Thermo Scientific DynaDrive technology in the future. 

The manufacturing facility is hoping to set a precedent of quality control and good practices, with processes meeting and exceeding current regulations from the China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration, and authorities in Europe and elsewhere.  

“Thermo Fisher has been in China for 40 years, serving this market through its bioproduction, clinical research and pharma services businesses,” commented Hann Pang, President, Thermo Fisher China. “Committed to our ‘in China, for China’ localization strategy, we are enhancing our workflow capabilities to fully support pharmaceutical and biotechnology companies in China and worldwide in helping more local innovations go global.”

Thermo Fisher provides complete end-to-end contract development and manufacturing, the new site in Hangzhou demonstrates the global scale of this capability as well as ensuring the advanced delivery of medicine to patients. 

Mentioned Companies
Thermo Fisher Scientific Inc.
View company profile
Lucy Chard
Digital Editor - Pharma

Related News